SCHEMBL19960792

SCHEMBL19960792

Nc1ccc(N2CCN(C(=O)OCc3ccccc3)CC2=O)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP2C19 P33261 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
TMEM97 Q5BJF2 6/20 0.44
SIGMAR1 Q99720 6/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
GRIN2B Q13224 5/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5592319 0.85 TMEM97 (0.43) SMN1; SMN2MEN1KMT2ANPSR1TMEM97
SCHEMBL5836154 0.85 MEN1 (0.53) SMN1; SMN2MEN1KMT2ACYP2C19ALDH1A1
SCHEMBL1949475 0.82 HPGD (0.56) SMN1; SMN2MEN1KMT2ACYP2C19ALDH1A1
SCHEMBL6323472 0.82 MEN1 (0.48) SMN1; SMN2MEN1KMT2ACYP2C19ALDH1A1
SCHEMBL4750456 0.80 HDAC1 (0.50) SMN1; SMN2MEN1KMT2ACYP2C19ALDH1A1
SCHEMBL31106295 0.80 TMEM97 (0.39) MEN1KMT2ANPSR1TMEM97SIGMAR1
SCHEMBL19946670 0.80 TMEM97 (0.39) MEN1KMT2ANPSR1TMEM97SIGMAR1
SCHEMBL3767269 0.80 TMEM97 (0.47) SMN1; SMN2MEN1KMT2ACYP2C19ALDH1A1
SCHEMBL1393916 0.80 GABRP (0.39) SMN1; SMN2ALDH1A1HRH1HRH3
SCHEMBL5592397 0.79 TMEM97 (0.47) SMN1; SMN2MEN1KMT2ACYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111333627-B Substituted 2-hydro-pyrazole derivatives as anticancer agents 正大天晴药业集团股份有限公司 2024-09-13 CN disclosed
CN-111333627-A Substituted 2-hydro-pyrazole derivatives as anti-cancer agents 正大天晴药业集团股份有限公司 2020-06-26 CN disclosed
CN-107428731-B Substituted 2-hydro-pyrazole derivatives as anti-cancer agents 正大天晴药业集团股份有限公司 2020-05-05 CN disclosed
US-9969719-B2 Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2018-05-15 US disclosed
US-20180072707-A1 SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072707-A1 SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG CDK4, CDK6, CDK3 SMN1; SMN2 2913/4885MEN1 3260/4885KMT2A 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.